| Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene G Cartron, L Dacheux, G Salles, P Solal-Celigny, P Bardos, P Colombat, ... Blood, The Journal of the American Society of Hematology 99 (3), 754-758, 2002 | 2434 | 2002 |
| Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia JF Seymour, TJ Kipps, B Eichhorst, P Hillmen, J D’Rozario, S Assouline, ... New England Journal of Medicine 378 (12), 1107-1120, 2018 | 963 | 2018 |
| From the bench to the bedside: ways to improve rituximab efficacy G Cartron, H Watier, J Golay, P Solal-Celigny Blood 104 (9), 2635-2642, 2004 | 681 | 2004 |
| Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship S Dall’Ozzo, S Tartas, G Paintaud, G Cartron, P Colombat, P Bardos, ... Cancer research 64 (13), 4664-4669, 2004 | 543 | 2004 |
| Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma S Le Gouill, C Thieblemont, L Oberic, A Moreau, K Bouabdallah, ... New England Journal of Medicine 377 (13), 1250-1260, 2017 | 416 | 2017 |
| Rituximab plus lenalidomide in advanced untreated follicular lymphoma F Morschhauser, NH Fowler, P Feugier, R Bouabdallah, H Tilly, ... New England Journal of Medicine 379 (10), 934-947, 2018 | 354 | 2018 |
| A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies HS Walter, SA Rule, MJS Dyer, L Karlin, C Jones, B Cazin, P Quittet, ... Blood, The Journal of the American Society of Hematology 127 (4), 411-419, 2016 | 282 | 2016 |
| Clinical radioimmunotherapy—the role of radiobiology JP Pouget, I Navarro-Teulon, M Bardiès, N Chouin, G Cartron, A Pèlegrin, ... Nature reviews Clinical oncology 8 (12), 720-734, 2011 | 279 | 2011 |
| Glofitamab for relapsed or refractory diffuse large B-cell lymphoma MJ Dickinson, C Carlo-Stella, F Morschhauser, E Bachy, P Corradini, ... New England Journal of Medicine 387 (24), 2220-2231, 2022 | 275 | 2022 |
| Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients G Salles, F Morschhauser, T Lamy, N Milpied, C Thieblemont, H Tilly, ... Blood, The Journal of the American Society of Hematology 119 (22), 5126-5132, 2012 | 264 | 2012 |
| Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study FA Morschhauser, G Cartron, C Thieblemont, P Solal-Céligny, C Haioun, ... Journal of Clinical Oncology 31 (23), 2912-2919, 2013 | 245 | 2013 |
| Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial V Ribrag, S Koscielny, J Bosq, T Leguay, O Casasnovas, LM Fornecker, ... The Lancet 387 (10036), 2402-2411, 2016 | 207 | 2016 |
| Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial G Damaj, R Gressin, K Bouabdallah, G Cartron, B Choufi, E Gyan, ... Journal of clinical oncology 31 (1), 104-110, 2013 | 205 | 2013 |
| A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma E Bachy, S Le Gouill, R Di Blasi, P Sesques, G Manson, G Cartron, ... Nature medicine 28 (10), 2145-2154, 2022 | 204 | 2022 |
| Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study AP Kater, JQ Wu, T Kipps, B Eichhorst, P Hillmen, J D’rozario, S Assouline, ... Journal of Clinical Oncology 38 (34), 4042-4054, 2020 | 198 | 2020 |
| Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study GA Salles, F Morschhauser, P Solal-Céligny, C Thieblemont, T Lamy, ... Journal of clinical oncology 31 (23), 2920-2926, 2013 | 182 | 2013 |
| Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study G Cartron, S de Guibert, MS Dilhuydy, F Morschhauser, V Leblond, ... Blood, The Journal of the American Society of Hematology 124 (14), 2196-2202, 2014 | 177 | 2014 |
| R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma T Lamy, G Damaj, P Soubeyran, E Gyan, G Cartron, K Bouabdallah, ... Blood, The Journal of the American Society of Hematology 131 (2), 174-181, 2018 | 165 | 2018 |
| Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000) J Radford, A Davies, G Cartron, F Morschhauser, G Salles, R Marcus, ... Blood, The Journal of the American Society of Hematology 122 (7), 1137-1143, 2013 | 161 | 2013 |
| Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study MS Czuczman, L Fayad, V Delwail, G Cartron, E Jacobsen, ... Blood, The Journal of the American Society of Hematology 119 (16), 3698-3704, 2012 | 159 | 2012 |
